triple-negative early breast cancer research hub

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)

This study is for people with a type of early breast cancer called triple-negative. It compares a new treatment combination, sacituzumab govitecan and pembrolizumab, with standard chemotherapy to see which works better. We want to find the most effective way to treat this cancer.